AMRX Q2 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$414M+59.2% YoY

Gross Profit

$178M43.1% margin

Operating Income

-$181M-43.8% margin

Net Income

-$219M-53.0% margin

EPS (Diluted)

$-1.73

QoQ Revenue Growth

+50.4%

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$119M

Stock-Based Comp.

$160M

Balance Sheet

Total Assets

$4.5B

Total Liabilities

$3.6B

Stockholders' Equity

$495M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$414M	$260M	+59.2%
Gross Profit	$178M	$124M	+44.1%
Operating Income	-$181M	$45M	-505.9%
Net Income	-$219M	$37M	-686.0%

Revenue Segments

Oseltamivir

$40M23%

Diclofenac Sodium Gel

$32M19%

Yuvafem-Estradiol

$31M18%

Aspirin;Dipyridamole ER Capsul

$28M16%

Rytary Family

$21M12%

Epinephrine Auto-Injector Family (Generic Adrenaclick)

$19M11%